Chester County News and Community Website
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced that the first patient has been dosed in its Phase 2/3 GARDian3 clinical trial evaluating OCU410ST, a gene therapy candidate designed …
Ocugen Doses First Patient in Pivotal Trial for Stargardt Gene Therapy Read More
MALVERN, PA — In a major scientific advance, Progenra Inc. has announced the discovery of a novel class of small-molecule drugs designed to restore the function of mutant forms of …
Progenra Breakthrough Offers New Hope for Parkinson’s Disease and Beyond Read More
WASHINGTON, D.C. — In a groundbreaking effort to revolutionize brain repair, the Advanced Research Projects Agency for Health (ARPA-H), part of the U.S. Department of Health and Human Services (HHS), …
ARPA-H Launches Ambitious Program to Regenerate Brain Tissue and Restore Neurological Function Read More
PLYMOUTH MEETING, PA — New research published in the July 2025 issue of JNCCN—Journal of the National Comprehensive Cancer Network offers encouraging news for men diagnosed with nonmetastatic prostate cancer. …
Study Finds Most Prostate Cancer Patients Following NCCN Guidelines Live Long, Healthy Lives Read More
HARRISBURG, PA — Governor Josh Shapiro announced this week that Pennsylvania is now a full participant in three major multistate licensure compacts, a move designed to address critical health care staffing …
Pennsylvania Fully Joins Health Care Licensure Compacts to Strengthen Workforce, Expand Access to Care Read More
CHARLEROI, PA — The Pennsylvania Department of Drug and Alcohol Programs (DDAP) recently announced a $1.5 million investment to expand drop-in center services for individuals with substance use disorder (SUD) …
Pennsylvania Invests $1.5 Million to Expand SUD Drop-In Services in Southwestern Counties Read More
HARRISBURG, PA — The Pennsylvania Department of Drug and Alcohol Programs (DDAP) has announced a groundbreaking move to expand access to substance use disorder (SUD) treatment across the Commonwealth by …
Pennsylvania Authorizes First Telehealth-Only License to Expand Substance Use Disorder Treatment Read More
PHILADELPHIA, PA — This June, as we observe Post-Traumatic Stress Disorder (PTSD) Awareness Month, a convergence of anniversaries provides a solemn opportunity for reflection. In 2025, we will commemorate the …
The Unseen Scars of 250 Years of Service: PTSD and the Opioid Crisis Read More
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has successfully completed enrollment in the Phase 3 SELVA clinical trial of QTORIN™ 3.9% rapamycin anhydrous gel, a potential breakthrough treatment for …
Palvella Therapeutics Announces Completion of Phase 3 SELVA Trial for QTORIN Rapamycin Read More
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has launched a Phase 1a/1b clinical program to evaluate the safety and efficacy of ATI-052, an investigational bispecific anti-TSLP/IL-4R antibody that could …
Aclaris Therapeutics Begins Phase 1a/1b Trial for Investigational Bispecific Antibody ATI-052 Read More